Compare Riot Platforms Inc (RIOT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Riot Platforms Inc vs TG Therapeutics Inc — how do they compare? Riot Platforms Inc trades at $21.83 (market cap $8.35B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Riot Platforms Inc and TG Therapeutics Inc are close in size by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals.
| RIOT | TGTX | |
|---|---|---|
Market Cap | $8.35B | $8.53B |
Sector | Technology | Health |
52-Week High | $28.67 | $59.06 |
52-Week Low | $11.83 | $26.94 |
Enterprise Value | $8.76B | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RIOT Platforms trades at $22.26, up 2.11% today, with a bullish technical signal from moving averages. The stock shows strong analyst support with 94.7% buy ratings and a $33 consensus price target. Recent news highlights a transformative $9.1 billion AI data center deal with Anthropic, shifting focus from Bitcoin mining to high-margin AI infrastructure. However, fundamental challenges persist with negative net income margins and consecutive earnings misses.
The outlook balances significant AI-driven growth potential against current profitability concerns. The Anthropic partnership provides long-term revenue visibility but execution risks remain. With the stock trading near analyst price targets, upside depends on successful AI transition and improved financial performance. Key risks include competitive pressures, regulatory uncertainty, and continued cash flow challenges.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
